Related Experiment Video
Updated: Jan 2, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.0K
Antiprogramed cell death-1 therapy with microspheres for metastatic liver tumors
Hiroteru Kamimura1, Nobutaka Takeda1, Takashi Owaki1
1Division of Gastroenterology and Hepatology Niigata University Graduate School of Medical and Dental Sciences Niigata Japan.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology
|December 14, 2019
Summary
Anti-programmed cell death-1 therapy using microspheres effectively treats metastatic liver tumors. This innovative approach offers a promising option for patients with advanced liver cancer.
Area of Science:
- Oncology
- Immunotherapy
- Drug Delivery Systems
Background:
- Metastatic liver tumors present a significant clinical challenge.
- Current treatment options for advanced liver cancer have limitations.
Purpose of the Study:
- To evaluate the efficacy of anti-programmed cell death-1 (PD-1) therapy delivered via microspheres for metastatic liver tumors.
Main Methods:
- Utilized microsphere-based drug delivery for anti-PD-1 agents.
- Assessed treatment response in a model of metastatic liver cancer.
Main Results:
- Anti-PD-1 therapy encapsulated in microspheres demonstrated significant effectiveness.
- Microsphere delivery enhanced the therapeutic impact on liver tumors.
Conclusions:
- Microsphere-encapsulated anti-PD-1 therapy is a viable and effective strategy for managing metastatic liver tumors.
- This method shows potential for improving outcomes in liver cancer treatment.
